Search company, investor...

Metabolic Technologies


Acq - Fin | Alive

Total Raised


About Metabolic Technologies

Metabolic Technologies, Inc.'s (MTI) goal is to position itself as a company in the development of biochemicals that can enhance human health, performance, and well-being that are marketed to the nutraceutical and cosmeceutical markets.

Headquarters Location

2711 S. Loop Drive, Suite 4400

Ames, Iowa, 50010,

United States

Missing: Metabolic Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Metabolic Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Metabolic Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metabolic Technologies is included in 1 Expert Collection, including Vitamin & Supplement Startups.


Vitamin & Supplement Startups

662 items

Metabolic Technologies Patents

Metabolic Technologies has filed 34 patents.

The 3 most popular patent topics include:

  • Dietary supplements
  • Rare diseases
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics




Rehabilitation medicine, Dietary supplements, Nutrition, Geriatrics, Diabetes


Application Date


Grant Date



Related Topics

Rehabilitation medicine, Dietary supplements, Nutrition, Geriatrics, Diabetes



Latest Metabolic Technologies News

Ingredient from buckwheat shows immune fitness promise via unique pathway, developer asserts

Jul 2, 2020

By Hank Schultz An ingredient new to the market could help support immune health via a unique pathway, according to the developers. The ingredient, dubbed 2-HOBA, is said to foster immune fitness by improving vascular system function. The ingredient was discovered via the work of Dr Naji Abumrad, MD, a surgeon at Vanderbilt University. The ingredient’s development was until recently housed within a company called Metabolic Technologies, which is a spinoff of Iowa State University. Now the ingredient is being pushed by a company called Big Bold Health, which is the brainchild of Jeffrey Bland, PhD, who is also the president of the Personalized Medicine Institute. Metabolic Technologies itself was recently acquired by branded ingredient manufacturing and marketing firm TSI Health, which Bland said is cooperating in the new ingredient’s development. Unique phytochemical The molecule, 2-HOBA, or 2-hydroxybenzylamine, is found is a number of plant sources. But Bland said this particular phytochemical is found in high concentrations in a particular heirloom food crop called tartary buckwheat. Bland said the ingredient came out of Dr Abumrad’s work early work on HMB, or beta-hydroxy beta-methylbutyric acid. Dr Abumrad’s early interest in this ingredient had to do with his specialty in obesity and bariatric surgery and the ability of HMB to ameliorate muscle loss post surgery. This ingredient came to be branded as myHMB, and was the focus of TSI’s recent acquisition of Metabolic Technologies. Dr Abumrad also started looking for other bioactive molecules from natural sources that could help his patients. “Dr Abumrad had occasion to look at some of the ingredients that had been found in traditional ancient food crops and in particular buckwheat stood out. Buckwheat had a history of helping to lower people’s blood pressure. Was that just because people changed their diets, or was there something special in the buckwheat?” ​ Bland said. (As a side note, Dr Abumrad has been in the news lately for his friendship with the singer Dolly Parton, who because of her connection to him made a $1 million donation to Vanderbilt ​ ​in April ​to support its coronavirus research efforts.) Bland said TSI is driving the development of 2-HOBA as an alternative blood pressure drug. He said the company has filed an IND and is beginning its clinical trial development. But Bland said he was much more interested in the nutritional aspects of the substance. “We are much more interested in the food related effects at a much lower dose,” ​Bland said. “My interest in 2-HOBA wasn’t specially around blood pressure. Rather I saw it as one of the few substances that could be seen as an immune system rejuvenating substance,”​ he said. Working on the levuglandins Bland the mechanism at work has to do with 2-HOBA’s effect on a family of reactive aldehydes in the body called levuglandins. 2-HOBA, which is technically described as a “selective dicarbonyl electrophile scavenger,”​ is able to surround and neutralize these potentially damaging molecules, or ‘quench’ them, to use Bland’s characterization. He said the mechanism was different from what is commonly associated with the class of phytochemicals known as antioxidants. The levuglandins arise from the oxidation of fatty acids in the body. In a situation of systemic, low level inflammation which is component of many lifestyle-based diseases that plague Western society, an overabundance of these levuglandins can affect immune system performance via a complex interaction that involves the blood vessels, Bland said. “You wouldn’t necessarily think that the compliance of our blood vessels is tied to our immune system state. When the immune system is aroused it communicates that situation to the endothelial cells,” ​Bland said. In the presence of a pathogenic attack, the blood vessels constrict, raising blood pressure to help more of the specialized immune system cells to circulate faster and arrive where they’re needed in greater numbers. But the loop can work in reverse, too, leaving the immune system primed for an attack which hasn’t come. “The you get what we call sterile inflammation, or inflammation that arises without an infection,” ​Bland said. Bland said 2-HOBA has shown promise in breaking this cycle, allowing blood pressure to recede naturally and the immune system to return to resting, healthful state, rather than being overly stimulated or ‘worn out,’ to use an oversimplification. “You have to break the loop of the dog chasing its tail, so to speak, so the dog can rest,”​ Bland said. So, with good news on the mechanism of action and safety and tolerability fronts ​​, where can one get commercial quantities of this ingredient? Bland said it is found at small levels in many varieties of buckwheat, but is found at much higher levels in a particular strain known as tartary buckwheat. Rediscovering a crop Tartary buckwheat, like other varieties of the plant, originated in Central Asia and had been a small part of the human agricultural picture for thousands of years. It was a popular food crop in Colonial times because it was prolific and easy to grow on many different soil types and didn’t require much in the way of inputs. But it grew in a willowy fashion and so was harder to harvest. Over the years it had lost out to more mainstream crops like wheat and oats which had been bred for shorter, stouter and even length stems that stood up straight for the combine to neatly nip off the seed heads. “Also, it is a very phytochemical right plant and as a result it has a lot of bitter, off flavor notes that don’t match the tastes of modern palates,” ​Bland said. “Over the years it had virtually disappeared,”​ he added. The botanical might have vanished from the scene altogether were it not for the efforts aficionado Sam Beer, a retired Cornell University professor turned farmer in upstate New York. Beer has been growing tartary buckwheat for a number of years on his farm and has enough capacity for Big Bold Health to get a start on commercial scale extraction. Bland’s plan is to build on Beer’s start and the knowledge he has acquired with the goal of creating a cooperative of farmers that can grow the crop. “Sam was the only person that we could find who was growing organic traditional tartary buckwheat,”​ Bland said. There’s a learning curve, which includes how to best harvest the plants that in early times were cut by hand. Beer’s early attempts at mechanical harvesting were frustrating because the plant, which grew tall, had a tendency to be lying down by the time it was ready to harvest. So running a conventionally set up combine over the field tended to knock many of the seeds off onto the ground. Direct to consumer brand Bland said Beer has expanded his acreage and several other area farmers are on board. The plan is to offer the finished products direct to consumer under the Big Bold Health name. Bland said that effort is being supported by a clinical trial that is underway in the Seattle area which is using Big Bold Health’s finished dietary supplement, which supplies a dose of 2-HOBA and the other phytochemicals found in the plant that he said corresponds to eating a 1/4 lb serving of tartary buckwheat. Big Bold Health is selling the supplement branded as HTB Rejuvenate on its website. The supplement also includes a dose of myHTB and supplies all of the phytochemicals found in tartarty buckwheat, which along with 2-HOBA include rutin, quercetin, hesperidin, luteolin and diosmin. The company is also selling Dutch Harbor Omega fish oil capsules, made via a dedicated supply chain from the Aleutian Islands. And a shake mix version of the HTB Rejuvenate product is in the works. “I have always wanted to try to find a way to redefine health away from disease. I thought I would give it one more shot with a direct to consumer opportunity,”​ Bland said. Copyright - Unless otherwise stated all contents of this web site are © 2020 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Metabolic Technologies Frequently Asked Questions (FAQ)

  • Where is Metabolic Technologies's headquarters?

    Metabolic Technologies's headquarters is located at 2711 S. Loop Drive, Suite 4400, Ames.

  • What is Metabolic Technologies's latest funding round?

    Metabolic Technologies's latest funding round is Acq - Fin.

  • How much did Metabolic Technologies raise?

    Metabolic Technologies raised a total of $400K.

  • Who are the investors of Metabolic Technologies?

    Investors of Metabolic Technologies include TSI Group and Iowa State University Research Park.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.